From Earlier: Rosetta Genomics to Raise $2.2 Million in Registered Direct Offering

Rosetta Genomics, Ltd.

yesterday announced it has entered into definitive agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share in a registered direct offering. The offering is expected to close on or about May 22, 2012, subject to the satisfaction of customary closing conditions. Rosetta plans to use the net proceeds from the offering primarily to fund its operations and for other general corporate purposes, including, but not limited to, repayment or refinancing of existing indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development and product development.